only proven therapy for macular edema due to BRVO is macular grid argon laser photocoagulation, but the clinical outcomes are often disappointing (average improvement in vision of 1.33 Snellen lines) [16] . A recent addition to the options for treatment of macular edema due to BRVO has been intraocular injection of corticosteroids. We tried intravitreal triamcinolone acetonide to treat BRVO with associated macular edema and evaluated its effect.
MATERIALS AND METHODS

Patient selection
The comparative nonrandomized clinical interventional study included 27 patients (27 eyes) with macular edema due to BRVO (only one quadrant involvement). There were 16 patients (13 men and 3 women; 16 eyes; 8 right eyes) in the study group and 11 patients (4 men and 7 women; 11 eyes; 7 right eyes) in control group. No cataract surgery was performed either before, in combination with, or after, intravitreal injection (IVI). Those patients enrolled in the study group agreed to accept an IVI of 4 mg triamcinolone acetonide. Patients who refused IVI of triamcinolone acetonide were assigned to the control group. In three eyes (27%) in the control group (cases 1, 3 and 10), retinal argon laser photocoagulation was performed for treating BRVO during follow-up, whereas others accepted only regular follow-up visit. The mean age of the study group was 55.75 Ϯ10.00 years and the mean age of the control group was 54.91 Ϯ 9.26 years. The mean follow-up duration was 103.00 Ϯ36.24 days (range, 54-186 days) in the study group and 94.55 Ϯ36.31 days (range, 60-154 days) in the control group (Table 1) .
We performed a series of ophthalmic examinations at study baseline and at repeated intervals afterwards as visual acuity [best-corrected visual acuity was determined from Snellen chart and calculated as the logarithm of minimal angle of resolution (logMAR)], slit-lamp biomicroscopy, pneumotonometry (Full auto Tonometer TX-F; Canon, New York, USA), ophthalmoscopy and optical coherence tomography (Stratus OCT TM III Model 3000; Zeiss Humphrey, New York, USA). For the study group, we performed the above examinations during the 1 st week postinjection, twice at 2-weekly intervals, and then at routine monthly intervals. For the control group, the same examinations were performed once a month. The main outcome measures were bestcorrected visual acuity, macular thickness assessed with optical coherence tomography (OCT), and postoperative complications.
Surgical procedure
IVI of triamcinolone acetonide was performed under sterile conditions in the operation theater with an operation microscope. Povidone-iodine (Saint-iodine ® ; Patron, Gangshan, Taiwan) was applied before IVI. Then, the patient was completely draped. We used a lid speculum to open the eye. Paracentesis into the anterior chamber was performed and some aqueous fluid was aspirated by using a 26-gauge needle with a 1.0-mL tuberculin syringe to decrease the volume of the eye. The injection of 4 mg (0.1 mL) crystalline triamcinolone acetonide (Kenacort TM -A; Bristol-Myers Squibb, Taipei, Taiwan) into the vitreous cavity was performed using a sharp 27-gauge needle through the pars plana, 4 mm from the limbus. After that, an antibiotic eyedrop (Tobramycin-Tobrex ® ; Alcon, Belgium) was applied.
Statistical analysis
Statistical calculations were performed using standard software (MS Excel 2003; Microsoft Co., Redmond, WA, USA). Data were compared using paired t-test. A p value Ͻ0.05 was considered to be significant.
RESULTS
In the study group, visual acuity measurements improved significantly (p Ͻ0.001) from 0.77 Ϯ0.43 logMAR preoperatively to a best postoperative visual acuity of 0.44 Ϯ0.43 logMAR. Fourteen eyes (87.5%) showed visual acuity improvement and two eyes (Table 2 ). In the control group, after argon laser photocoagulation or just continuous observation, only three eyes (27.27%) showed visual acuity improvement. Four eyes (36.36%) had the same visual acuity during follow-up compared with baseline. For four eyes (36.36%), visual acuity measurements after the baseline measurement were worse than those at the start of the study (Table 3 ). In the study group, the visual acuity was significantly increased postoperatively (p Ͻ0.001). On the other hand, the visual acuity of the control group did not vary significantly (p ϭ0.294) between baseline best-corrected visual acuity and best-corrected visual acuity during follow-up.
In all the cases in the study group, the decline of cotton wool spots, retinal hemorrhage, and macular edema were noted during fundus examination after IVI of triamcinolone acetonide ( (Table 2 ). In the control group, the foveal thickness measured by OCT between baseline and final measurements did not show significant resolution (p ϭ0.170). Baseline foveal thickness ranged from 215 to 717 m (mean, 428.27 Ϯ167.65 m). Final foveal thickness ranged from 192 to 725 m (mean, 396.91 Ϯ175.28 m) with an average decrease of 6.48% in foveal thickness ( Table 3) .
Recurrence of macular edema and a decrease in visual acuity occurred in one case of the study group 3 months postoperatively. Subsequently, the patient accepted a second injection of triamcinolone acetonide. After that, the macular edema subsided and visual acuity improved again.
In the study group, no obvious complication was noted postoperatively, but three patients (18.75%) had ocular hypertension (intraocular pressure у22 mmHg) which could be controlled to a normal range by antiglaucomatous medication. No pre-existing cataracts progressed and no cataract formation was noted in the study group during follow-up and no eye required cataract surgery. No serious side effects, such as postoperative endophthalmitis or retinal detachment, occurred.
DISCUSSION
Intravitreal triamcinolone acetonide was first used by Antcliff et al to treat uveitic cystoid macular edema [17] ; consequently, many researchers tried intravitreal triamcinolone acetonide to treat macular edema caused by different diseases such as diabetic macular edema [18, 19] and proliferative diabetic retinopathy [20] . Intravitreal triamcinolone acetonide has also been used to treat retinal vasculitis caused by retinal vascular diseases such as Vogt-Koyanagi-Harada syndrome [21] , sympathetic ophthalmia [22] , central retinal vein occlusion [23] and diabetic papillopathy [24] , but studies mentioning BRVO are still rare.
Jonas et al injected 20-25 mg triamcinolone acetonide into 10 eyes of 10 patients with BRVO in the study group while 18 patients with BRVO in the control group did not receive IVI [25] . They found that visual acuity increased significantly in the study vs. control group during the follow-up period. There were no significant complications except that seven eyes (70%) in the study group had elevation of intraocular pressure (Ͼ21 mmHg) which was readily normalized by topical antiglaucomatous medication.
Lee and Shah examined the effect of triamcinolone acetonide IVI in six patients with cystoid macular edema secondary to BRVO [26] . Three of six eyes showed improvement in vision. All three patients without vision improvement accepted a second injection. All six eyes had an increase in visual acuity at the final follow-up visit. Five (83.3%) of six eyes showed an improvement of at least two lines of vision. OCT of five eyes (one patient was seen at a satellite office without OCT capabilities) showed a decrease of cystoid macular edema in four eyes (80%). One patient had a postoperative rise in intraocular pressure, requiring a trabeculectomy. In a retrospective study of 13 eyes of 13 patients (mean age, 68 years) who underwent IVI with 4 mg triamcinolone acetonide for macular edema due to BRVO, Cekic et al observed a significant decrease in retinal thickness in all cases with OCT, accompanied by a gain in final visual acuity in half the patients [27] . Table 2 . Clinical data of study group before and after intravitreal injection of triamcinolone acetonide From the results of the present study, we found that intravitreal triamcinolone acetonide may be effective in the treatment of macular edema and increase visual acuity in patients with branch retinal vein occlusion. It also appears effective in decreasing vascular leakage. All 16 patients in the study group showed a decrease in central foveal thickness in OCT examination. The patients in the study group experienced a significant increase in visual acuity (p Ͻ0.001), while those in the control group did not (p ϭ0.294).
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The anti-inflammatory reaction hypotheses of corticosteroid are as follows. First, it may reduce capillary permeability by increasing the activity and density of the tight junctions in the retinal capillary endothelium [28] . Second, it may inhibit the metabolic pathway of vascular endothelial growth factor, a major vascular permeability-increasing factor [29, 30] . Third, it may also attenuate leukostasis and blood-retinal barrier breakdown [31] . Our hypothesis for why intravitreal triamcinolone acetonide is more effective for early BRVO is as follows.
Intraretinal intercellular structures are disrupted due to chronic macular edema. Although numerous retinal cells are damaged due to capillary nonperfusion, partial retinal cell function and structure may be reversible if early resolution of macular edema can be reached by treating with intravitreal triamcinolone acetonide.
One patient in the study group suffered from recurrence of macular edema and a decrease in visual Reinjection of triamcinolone acetonide led to a visual acuity improvement and a reduction in macular thickness. This observation is similar to the study reported by SalinasAlaman et al, whose patient received a second injection after 3 months [32] .
In our case series, no toxic effects of triamcinolone acetonide on the retina and optic nerve were noted in the study group. Previous clinical and experimental studies also demonstrated the safety of using intraocular steroid [33] [34] [35] [36] [37] .
The most common side effect reported after IVI of triamcinolone acetonide is a rise in intraocular pressure. In our study, ocular hypertension (intraocular pressure у22 mmHg) occurred in three eyes (18.75%) . This problem could be controlled by topical antiglaucomatous treatment. Other studies also revealed similar observations [38] [39] [40] [41] .
An increase in cataract formation has been described in patients after IVI of triamcinolone acetonide.
Progression of cataract was observed in six of 26 eyes in a study by Challa et al [42] and in four of seven eyes in a study by Danis et al [43] . Jonas et al observed a progression in cataract in one of their patients, although it was not a significant change [44] . Park et al found a progression in one of 10 eyes [45] , and Martidis et al noted a similar finding in one of eight eyes [46] . However, in our study, we did not observe any cataract formation or deterioration in pre-existing cataracts in the study group.
Intraocular infection is one of the most severe complications after triamcinolone acetonide IVI. Moshfeghi et al [47] and Nelson et al [48] observed infectious endophthalmitis in their cases after intravitreal triamcinolone acetonide injection. Non-infectious endophthalmitis has also been reported by Nelson et al [48] , Moshfeghi et al [49] , Roth et al [50] , Chiu et al [51] and Sutter and Gillies [52] . In none of the eyes in our study group were postoperative infectious or non-infectious endophthalmitis observed. The advantages of intravitreal triamcinolone acetonide include avoiding systemic adverse effects, having simultaneously high concentrations of drug at the site of action, and no toxic effect on intraocular tissue.
The major limitations of our study are nonrandomized selection between study and control groups, small number of patients in both study and control groups, and the relatively short follow-up period. Further study with longer follow-up and a larger series is warranted to assess the long-term efficacy and safety of intravitreal triamcinolone acetonide.
CONCLUSION
The application of triamcinolone acetonide IVI showed a significant increase in visual acuity with a decrease in macular edema and vascular leakage in patients with BRVO. A side effect observed in our study was an elevation of intraocular pressure, which can be readily resolved by topical antiglaucomatous medication. The results of this study suggest that intravitreal triamcinolone acetonide may be an alternative therapeutic option for patients with macular edema due to BRVO. 
